BioPharmSignal logoBioPharmSignal

Biotech News

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

Minerva Neuroscience (NERV)Minerva NeuroscienceConference / presentation

Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London.

Related news

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

TNXPTonix Pharmaceuticals2026-09-02 11:00 EST

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

HRMYHarmony Biosciences2026-08-27 12:05 EST

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

TNXPTonix Pharmaceuticals2026-11-04 12:00 EST

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

NERVMinerva Neuroscience2026-10-28 11:00 EST

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

ECORelectroCore2026-09-10 12:00 EST

electroCore to Participate at H.C. Wainwright Global Investment Conference

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

ALKSAlkermes plc2026-11-03 21:00 EST

Alkermes to Present at Upcoming Investor Conferences

View all latest news

Minerva Neuroscience

CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options. Roluperidone Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such...

Recent company news

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

NERVMinerva Neuroscience2026-10-28 11:00 EST

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

Stock data

Close
2.30 USD
Market cap
221.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States